Kelowna, British Columbia– February 13, 2020 – Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, announces that its DehydraTECHTM-enabled CBD infused powders are now available for sale across the USA…
Lexaria is technology for improved delivery of bioactive compounds.
CSE:LXX; OTCQX:LXRP
[stock_market_widget type=”single” symbol=”LXX.CN” template=”header” color=”blue” refresh_frequency=”0″] [stock_market_widget type=”single” symbol=”LXRP” template=”header” color=”blue” refresh_frequency=”0″]
Welcome to Lexaria Bioscience Corp.
Lexaria Bioscience Corp. (CSE:LXX; OTCQX:LXRP) has developed and out-licenses its disruptive and cost-effective DehydraTECH™ technology that promotes healthier administration methods, lower overall dosing and higher effectiveness of ingestible drugs and other beneficial molecules.
Lexaria’s DehydraTECHTM delivery technology is protected by a robust suite of patents granted or pending worldwide and is proven effective in multiple international studies in greatly assisting rapidity and quantity of absorption of a range of lipophilic (i.e., fat-soluble), bioactive molecules. By significantly enhancing the performance and experience with oral ingestion, Lexaria’s DehydraTECH delivery technology offers a viable and often healthier alternative to other delivery methods for bioactive substances in widespread use today such as inhalational delivery through smoking.
About DehydraTECH
Lexaria’s patented technology, DehydraTECH™ delivers these important benefits:
Masks taste/odor
Eliminates the strong tastes/odors of lipophilic compounds, without the need for unwanted sugar or sweeteners
Reduces time of onset
Effects are felt within 15-20 min vs. 60-120 min.
Avoids first-pass liver metabolism
Initial testing indirectly evidences DehydraTECH may deliver ingested molecules through the lymphatic system instead of being subject to immediate “first pass” liver exposure, potentially mitigating unwanted side effects and reducing liver biotransformation.
Increases bio-absorption
Bio-absorption increases up to 3 – 10X, to equate or exceed that of other routes of administration like inhalational delivery.
Lexaria’s disruptive new technology DehydraTECH can be licensed to improve existing drug delivery through orally-ingested products; or create revolutionary new ones.
DehydraTECH Commercial Applications
Lexaria’s DehydraTECH™ is designed specifically for formulating and delivering lipophilic (i.e. fat-soluble) drug payloads. It is patented or patent-pending for use with a broad range of bioactive molecules, including but not limited to:
Latest News
Lexaria Awards Options
Kelowna, British Columbia– February 7, 2020 – Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, announces that it has issued 550,000 stock options to an insider of the Company for…
Lexaria Bioscience Corp. and Cannadips Cannabis Announce Expanded Relationship Into Cannabis Oral Pouch & Dip Category
Kelowna, British Columbia– January 22, 2020 – Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, announces that it has reached a new definitive agreement to provide its patented DehydraTECHTM technology…